Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives
Funding Number
5P20GM121322
Funding Sponsor
National Institute of General Medical Sciences
Third Author's Department
Biotechnology Program
Find in your Library
https://doi.org/10.3389/fimmu.2024.1434771
Document Type
Research Article
Publication Title
Frontiers in Immunology
Publication Date
1-1-2024
doi
10.3389/fimmu.2024.1434771
Abstract
The gut microbiome plays a significant role in the pathogenesis of pancreatic ductal adenocarcinoma (PDAC), influencing oncogenesis, immune responses, and treatment outcomes. Studies have identified microbial species like Porphyromonas gingivalis and Fusobacterium nucleatum, that promote PDAC progression through various mechanisms. Additionally, the gut microbiome affects immune cell activation and response to immunotherapy, including immune checkpoint inhibitors and CAR-T therapy. Specific microbes and their metabolites play a significant role in the effectiveness of immune checkpoint inhibitors (ICIs). Alterations in the gut microbiome can either enhance or diminish responses to PD-1/PD-L1 and CTLA-4 blockade therapy. Additionally, bacterial metabolites like trimethylamine N-oxide (TMAO) and lipopolysaccharide (LPS) impact antitumor immunity, offering potential targets to augment immunotherapy responses. Modulating the microbiome through fecal microbiota transplantation, probiotics, prebiotics, dietary changes, and antibiotics shows promise in PDAC treatment, although outcomes are highly variable. Dietary modifications, particularly high-fiber diets and specific fat consumption, influence microbiome composition and impact cancer risk. Combining microbiome-based therapies with existing treatments holds potential for improving PDAC therapy outcomes, but further research is needed to optimize their effectiveness.
Recommended Citation
APA Citation
Tabrizi, E.
Pourteymour Fard Tabrizi, F.
Mahmoud Khaled, G.
Sestito, M.
...
(2024). Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives. Frontiers in Immunology, 15,
10.3389/fimmu.2024.1434771
https://fount.aucegypt.edu/faculty_journal_articles/6290
MLA Citation
Tabrizi, Eileen, et al.
"Unraveling the gut microbiome’s contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives." Frontiers in Immunology, vol. 15, 2024,
https://fount.aucegypt.edu/faculty_journal_articles/6290
Comments
Review. Record derived from SCOPUS.